The Venture Codex Logo

The Venture Codex

Overview

Equity crowdfunding platform for private investors.

Founded

2018

Deals · 12mo

1

Links

Stage focus

Crowdfunding
Seed

Geographic focus

Ireland

Sector focus

Investment portfolio

  • Moby Bikes

    Led · Crowdfunding · Nov 2025

    Founded in 2020, Moby Bikes runs a fleet of about 2,000 shared bikes throughout Ireland and recently relaunched 150 e-cargo bikes in the Netherlands following the acquisition of Cargoroo. The service has surpassed 1.5 million rides and accumulated more than 100,000 registered users, and its vehicles are used by customers such as Domino’s Pizza, the Dutch Police and the European Parliament. Management plans to add roughly 300 bikes per year through 2029, lifting the fleet to more than 3,000 units, while also aiming to acquire one competitor annually and bid on EU-funded cargo-bike tenders. Revenue is projected to nearly quadruple by 2029, reflecting expansion across four countries and three business lines. Last year Moby integrated its Dublin bikes into the FreeNow app, further increasing distribution. Earlier investors from a 2021 crowdfunding round have reportedly seen an eightfold return, and the company is backed by Enterprise Ireland. The new fundraising will support continued fleet growth, European roll-outs of Cargoroo’s 600 historic locations, and pursuit of zero-emission delivery opportunities.

  • Altach Biomedical

    Participated · Seed · May 2024

    Altach Biomedical is a spin-out of Trinity College Dublin developing novel biomimetic collagen scaffolds to encourage innate regeneration of musculoskeletal tissues, particularly articular cartilage. The scaffold is designed to mimic native cartilage properties and provide an alternative to traditional cartilage-repair methods. Company leaders say the technology could reduce recovery times, lower the need for invasive surgeries, and improve patient outcomes. Altach reports more than a decade of R&D, progressing the technology from proof-of-concept to pre-clinical evaluation, and has recently been granted a US patent. The company intends to scale up manufacturing and validate the product in advance of clinical use. Altach has raised €1.2m to bring its product closer to market and progress towards clinical trials and eventual commercialisation.

Insights

Team